Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04040673 | RAman For Thyroid cancER(RAFTER) | withdrawn | — | 0 | Gloucestershire Hospitals NHS Foundation TrustOTHER | 1 | Sep 17, 2026 |
| clinicaltrials |
| NCT05363709 | BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 12, 2026 | clinicaltrials |
| NCT05774535 | Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery(TIROVASC) | withdrawn | — | 0 | Istituto Auxologico ItalianoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06276946 | Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia | withdrawn | N/A | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05849142 | Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac(OPC-V) | withdrawn | N/A | 0 | University of MiamiOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer(ANAPLAST-NEO) | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | withdrawn | Phase 1 | 0 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04868045 | Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Feb 21, 2023 | clinicaltrials |
| NCT05512767 | A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation | withdrawn | N/A | 0 | Mayo ClinicOTHER | 0 | Jan 6, 2023 | clinicaltrials |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT00373711 | Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA | withdrawn | — | 0 | Stanford UniversityOTHER | 0 | Jun 21, 2022 | clinicaltrials |
| NCT04224792 | Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors | withdrawn | N/A | 0 | Mayo ClinicOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT02289807 | Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy | withdrawn | N/A | 0 | Sun Yat-sen UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | withdrawn | Phase 2 | 0 | Antonio FojoOTHER | 0 | Oct 13, 2021 | clinicaltrials |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | withdrawn | Phase 2 | 0 | The University of Hong KongOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma | withdrawn | N/A | 0 | Medstar Health Research InstituteOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT00181220 | Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 2 | May 18, 2020 | clinicaltrials |
| NCT02390739 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 16, 2019 | clinicaltrials |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03611205 | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02628912 | Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Jan 4, 2018 | clinicaltrials |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Julie E. Bauman, MD, MPHOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT01767961 | Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Aug 10, 2017 | clinicaltrials |
| NCT02726282 | Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT02119728 | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01994200 | Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients(ITCA-ThyCa) | withdrawn | Phase 1 / Phase 2 | 0 | Jewish General HospitalOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT02516774 | A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers(TAM-RT) | withdrawn | Phase 1 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01153945 | Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum | withdrawn | — | 0 | Meir Medical CenterOTHER | 1 | Apr 7, 2015 | clinicaltrials |
| NCT01953952 | Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 1 | Mar 20, 2015 | clinicaltrials |
| NCT01718223 | Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Sep 3, 2014 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials